Methods and Protocols · 2019 · 24 citations · 27 references
Life SciencesImmunologyOncologyImmunotherapyProteomicsTumor MicroenvironmentCancer BiomarkersCancer ProteomicsMass Spectrometric ImagingMass Spectrometry-based ProteomicsMolecular Tumor ProfilingTumor Immune MicroenvironmentMaldi-tof Mass SpectrometryMatrix-assisted Laser Desorption/ionizationMatrix-assisted Laser Desorption/ionization ImagingNon-small Cell Lung Cancer ImagingNon-small Cell Lung Cancer ImmunotherapyTumor Immune Microenvironment ProfilingTumor Microenvironment CharacterizationTumor Microenvironment Imaging
Advanced non-small-cell lung cancer (NSCLC) is generally linked with a poor prognosis and is one of the leading causes of cancer-related deaths worldwide. Since only a minority of the patients respond well to chemotherapy and/or targeted therapies, immunotherapy might be a valid alternative in the lung cancer treatment field, as immunotherapy attempts to strengthen the body's own immune response to recognize and eliminate malignant tumor cells. However, positive response patterns to immunotherapy remain unclear. In this study, we demonstrate how immune-related factors could be visualized from single NSCLC tissue sections (Biobank@UZA) while retaining their spatial information by using matrix assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI), in order to unravel the molecular profile of NSCLC patients. In this way, different regions in lung cancerous tissues could be discriminated based on the molecular composition. In addition, we linked visualization (MALDI MSI) and identification (based on liquid chromatography higher resolution mass spectrometry) of the molecules of interest for the correct biological interpretation of the observed molecular differences within the area in which these molecules are detected. This is of major importance to fully understand the underlying molecular profile of the NSCLC tumor microenvironment.
27
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin, Xiuli Zhang, Heiko Schuster et al. · Nature · 2014 · 2K citations · Full text
Life Sciences, Immunology, Oncology +10